Clinical Trials Logo

Affective Psychosis, Bipolar clinical trials

View clinical trials related to Affective Psychosis, Bipolar.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01196858 Completed - Clinical trials for Schizophrenia and Disorders With Psychotic Features

Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland

Start date: September 2010
Phase: N/A
Study type: Observational

During the 1990s, evidence began to emerge of the long duration of untreated illness prior to receiving treatment for patients with psychotic disorders. Studies across the world on first episode psychosis have consistently found an average of 1 - 2 years between the onset of psychotic symptoms and the start of treatment. Lengthy treatment delay has immediate implications such as unnecessary distress for patients and families, and may also compromise potential recovery when treatment is initiated.By understanding how and why substantial delays occur the investigators may be able to better design interventions to facilitate better earlier treatment. The components of DUP can be conceptualised as comprising 3 distinct intervals: help-seeking delay, referral delay and delay in mental health services. In this study the primary aim is to establish the level of DUP in nordland, and explore the components of this variable. Help-seeking delay will be investigated by interviewing patients presenting at the central mental health hospital in Nordland about their psychosis onset and pathways to care. Referral delay will be investigated by a questionnaire about the referral pratices among GPs in Nordland. Delays in mental health services will be investigated by focus group interviews with leaders and professionals at the 7 community mental health centers in Nordland. This knowledge is believed to be crucial for developing services that can reduce DUP and give this patient population earlier access to adequate treatment.

NCT ID: NCT00960375 Completed - Schizophrenia Clinical Trials

Smoking Cessation for Veterans With Severe and Persistent Mental Illness

Start date: April 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators have developed an intervention called Behavioral Treatment of Smoking Cessation in SPMI (BTSCS), an innovative intervention that supplements pharmacotherapy and education with contingency management and a multifaceted behavioral group treatment program that lasts for three months (24 group meetings). BTSCS is designed to address the cognitive, motivational, and social support problems characteristic of people with SPMI. The investigators propose to conduct a randomized trial for persons with SPMI that compares (1) BTSCS: a 6-month manualized smoking cessation program adapted from an effective substance abuse treatment program for this population to (2) StSST: a standard manualized smoking cessation program which reflects current best practices.

NCT ID: NCT00454883 Completed - Mania Clinical Trials

Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.

Start date: April 2007
Phase:
Study type: Observational

Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.

NCT ID: NCT00422214 Completed - Depression, Bipolar Clinical Trials

Phase III/Seroquel SR Bipolar Depression Monotherapy - US

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Depression for 8 weeks. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

NCT ID: NCT00422123 Completed - Mania Clinical Trials

Phase 3 /Seroquel SR Acute Mania Monotherapy - US

Start date: January 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

NCT ID: NCT00309686 Completed - Bipolar Disorder Clinical Trials

A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder

Start date: April 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while they are taking lithium or valproate. This study will also evaluate the effect of paliperidone ER compared with placebo on overall functioning, on how quickly a response is seen, on improvement in severity of illness, on health-related functional status, on depressive symptoms, and on psychotic symptoms. The relationship between blood levels and the effectiveness and safety of paliperidone ER will be evaluated, including the effect of food relative to time of taking the drug.